Business Wire

Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

31.10.2019 15:04:00 EET | Business Wire | Press release

Share

Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga ® is an effective alternative to cryoprecipitate for patients with severe bleeding during cardiac surgery. The data were recently published in the Journal of the American Medical Association (JAMA).1

Excessive bleeding is a major concern during surgery, and excessive blood loss and/or clotting factor consumption can lead to deficiency in the coagulation factor fibrinogen. This acquired fibrinogen deficiency (AFD) can be treated with plasma-derived cryoprecipitate or with fibrinogen concentrates. Data on the use of fibrinogen concentrates in AFD have been limited until now. fibryga ® is a highly purified, dual pathogen-inactivated, lyophilised human fibrinogen concentrate for intravenous infusion, with rapid reconstitution for effective correction of fibrinogen deficiency.

The latest data on the use of fibrinogen concentrates in AFD are from the FIBRES trial, a multicentre, single-blind, randomised, comparator-controlled trial conducted in Canada to assess noninferiority of fibryga ® compared to cryoprecipitate in patients undergoing cardiac surgery. The trial enrolled 827 participants at 11 centres in Canada. In the publication, Dr Jeannie Callum and colleagues show that in these bleeding patients, the mean number of blood component transfusions needed for treatment, did not differ in patients receiving fibryga ® or cryoprecipitate in the 24 hours after cardiopulmonary bypass (16.3 vs 17.0, respectively; p < 0.001 for noninferiority). There were no differences in adverse events in the two groups. The data met the study’s prespecified noninferiority criterion and led to early termination of the trial. Full results are available online here.

Previous studies evaluating efficacy and safety of fibrinogen concentrates for the treatment of patients with severe bleeding have been limited by study size. The FIBRES trial represents the largest randomised, comparator-controlled clinical trial of fibrinogen concentrates in severe bleeding; the final analysis includes more patients than in all previous studies combined.

The data are of particular importance for regions where cryoprecipitate is the current standard treatment for AFD, and support the use of fibryga® for management of bleeding in patients undergoing cardiac surgery.

fibryga® has a fixed, labelled content of fibrinogen and is double pathogen-inactivated. It supplied as a lyophilized powder that can be stored at room temperature and reconstituted within minutes. The reconstituted product is stable at room temperature for 24 hours. Conversely, Cryoprecipitate, must be thawed before use and must be used within 4 hours of thawing. The amount of Fibrinogen in Cryoprecipitate can vary considerably from preparation to preparation. In addition, the pooling of plasma during the preparation of cryoprecipitate carries potential risk of infectious transmission.

Olaf Walter, Board Member at Octapharma said that “patients undergoing major surgery are in a very vulnerable situation and the availability of convenient treatments is critical. These latest results add to the growing portfolio of positive data for fibryga® and we are proud to be able to contribute to the rapid and effective treatment for people experiencing excessive bleeding”

fibryga® is approved to treat congenital fibrinogen deficiency in 15 countries in the European Union, as well as in the US and Canada. In Switzerland, fibryga® is approved to treat both congenital fibrinogen deficiency and AFD.

About fibryga®
fibryga® is a novel fibrinogen concentrate produced from pooled plasma providing fast reconstitution, dual pathogen safety, high level of purity, and functionality for the treatment of patients where fast and efficacious replacement of fibrinogen is needed. Indication of use may differ by country. Please consult local product information for country specific information or contact an Octapharma representative.

About Octapharma
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:

  • Haematology (coagulation disorders)
  • Immunotherapy (immune disorders)
  • Critical care (bleeding management and functional volume replacement)

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.


1 Callum et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery - The FIBRES randomized clinical trial. JAMA 2019. doi:10.1001/jama.2019.17312. Published online October 21, 2019.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com

or

Oliver Hegener
oliver.hegener@octapharma.com
Tel: +41554512140

or

Ivana Spotakova
Communications Manager
Ivana.spotakova@octapharma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release

Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release

Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release

Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye